Kenneth Cohen, MD
Cardiovascular Disease · Lake Success, NYNPI 1265476261
Payments from drug & device makers
Across 295 payments — averaging $148.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$23K
- Boehringer Ingelheim Pharma GmbH & Co.kg$11K
- Boston Scientific$1K
- Lilly USA, LLC$1K
- Medtronic$991
- Boehringer Ingelheim$765
- plus $5K from 27 others
Across 4 payments — averaging $16,549 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$63K
- Novartis Pharma AG$3K
What the payments were for
- Food & beverage$9,05499%
- Education$440%
- Entertainment$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 117 | $23,458 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 3 | $11,182 |
| Boston Scientific | 38 | $1,359 |
| Lilly USA, LLC | 10 | $1,085 |
| Medtronic(2 entities) | 8 | $991 |
| Boehringer Ingelheim | 6 | $765 |
| Atricure, Inc. | 4 | $688 |
| Johnson & Johnson | 5 | $625 |
| Abbott | 8 | $605 |
| Novo Nordisk | 13 | $564 |
| Pfizer | 27 | $523 |
| Cvrx, Inc. | 5 | $426 |
| Amgen(2 entities) | 10 | $410 |
| GSK | 10 | $218 |
| Biotronik Inc. | 1 | $175 |
| AstraZeneca | 3 | $127 |
| Merck | 4 | $79 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $66 |
| Novartis | 3 | $64 |
| Keystone Dental Inc. | 1 | $43 |
| Seqirus USA Inc | 3 | $41 |
| Phathom Pharmaceuticals, Inc. | 2 | $39 |
| Insmed, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Itamar Medical Inc | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Irhythm Technologies, Inc. | 1 | $24 |
| AbbVie | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Philips North America LLC | 1 | $21 |
| Recor Medical Inc | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$1,564
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$688
- XARELTO$625
- MOUNJARO$580
- CardioInsight$539
- ATRICLIP LAA EXCLUSION SYSTEM$530
- ZEPBOUND$468
- WATCHMAN FLX$419
- Barostim Neo System$328
- Repatha$256
- WATCHMAN Access System$249
- Watchman$244
- AVEIR$186
- Acticor 7 VR-T DX$175
- AURORA EV-ICD MRI SURESCAN$158
- MitraClip$150
- LINQ II$139
- Reveal LINQ$126
- CardioMEMS HF System$123
- PRADAXA$115
How this compares
$43,782 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 24 | $800,824 |
| EliquisApixaban | 229 | $231,206 |
| JardianceEmpagliflozin | 135 | $178,415 |
| XareltoRivaroxaban | 117 | $139,915 |
| Repatha SureclickEvolocumab | 116 | $114,576 |
| FarxigaDapagliflozin Propanediol | 65 | $89,441 |
| OzempicSemaglutide | 58 | $73,027 |
| EntrestoSacubitril/Valsartan | 46 | $69,185 |
| VascepaIcosapent Ethyl | 47 | $32,344 |
| JanuviaSitagliptin Phosphate | 23 | $31,266 |
| WegovySemaglutide | 16 | $31,029 |
| Praluent PenAlirocumab | 32 | $24,869 |
| MultaqDronedarone Hcl | 12 | $21,096 |
| BrilintaTicagrelor | 15 | $19,123 |
| Atorvastatin Calcium | 1,249 | $13,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis, Paxlovid | $523 | $1,034,888279 claims |
| Boehringer IngelheimJardiance, Pradaxa | $765 | $183,015146 claims |
| Johnson & JohnsonXarelto | $625 | $139,915117 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $127 | $114,22497 claims |
| Novo NordiskOzempic, Wegovy | $564 | $104,05674 claims |
| NovartisEntresto, Diovan | $64 | $81,82958 claims |
| MerckJanuvia | $79 | $31,26623 claims |
| AbbVieSynthroid | $21 | $6,29090 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Lake Success
- Ronald DagostinoLake Success$814K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
- Szilard VorosStony Brook$3.7M
- Valentin FusterNew York$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.